ReviewWorld journal of gastroenterology2008
Colorectal cancer and dysplasia in inflammatory bowel disease.
Review in World journal of gastroenterology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 2 syntheses or guidelines pooled it, 146 citations in OpenAlex.
- Update from 2010 (standard operating procedure): protocol for the 2024 British Society of Gastroenterology Guidelines on colorectal surveillance in inflammatory bowel disease.BMJ open gastroenterology · 2024Guideline
- Colonic lesion characterization in inflammatory bowel disease: A systematic review and meta-analysis.World journal of gastroenterology · 2018Pooled it
- Optimizing management of Crohn's disease within a project management framework: results of a pilot study.Inflammatory bowel diseases · 2012Trial
- Risk Factors for Pouch Neoplasia in Patients With Inflammatory Bowel Disease: A Case-Control Study.Gastro hep advances · 2026Article
- A case of Crohn's-disease-associated anal canal cancer with p53-positive dysplasia: suggesting insights to stepwise carcinogenesis.Clinical journal of gastroenterology · 2025Article
- Article
- Review
- A case-control study of the association between the gut microbiota and colorectal cancer: exploring the roles of diet, stress, and race.Gut pathogens · 2024Article
- Perirectal Mucinous Adenocarcinoma After Subtotal-Colectomy for Crohn's Disease: A Case Report.Cureus · 2024Article
- Prognostic Factors in Prostate Cancer Associated with Ulcerative Colitis.Journal of clinical medicine · 2024Article
- Rectal carcinoma with dual differentiation toward enteroblastic and neuroendocrine features arising in a patient with ulcerative colitis: a case report.World journal of surgical oncology · 2022Article
- Involvement of integrin-activating peptides derived from tenascin-C in colon cancer progression.World journal of gastrointestinal oncology · 2021Review
- Epigenetic DNA Methylation ofInternational journal of molecular sciences · 2021Article
- Intestinal Regulatory T Cells.Advances in experimental medicine and biology · 2021Article
- Epigenetic histone modulation contributes to improvements in inflammatory bowel disease via EBI3.Cellular and molecular life sciences : CMLS · 2020Article
- Colorectal Cancer in Inflammatory Bowel Disease.Clinics in colon and rectal surgery · 2020Review
- Involvement of Integrin-Activating Peptides Derived from Tenascin-C in Cancer Aggression and New Anticancer Strategy Using the Fibronectin-Derived Integrin-Inactivating Peptide.Molecules (Basel, Switzerland) · 2020Review
- Comparative Evaluation of Colon Cancer Specific Antigen-2 Test and Chromocolonoscopy for Early Detection of Egyptian Patients with Colorectal Cancer.Anti-inflammatory & anti-allergy agents in medicinal chemistry · 2020Article
- Chronic Stress, Inflammation, and Colon Cancer: A CRH System-Driven Molecular Crosstalk.Journal of clinical medicine · 2019Review
- Peptide TNIIIA2 Derived from Tenascin-C Contributes to Malignant Progression in Colitis-Associated Colorectal Cancer via β1-Integrin Activation in Fibroblasts.International journal of molecular sciences · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Both ulcerative colitis and Crohn's disease carry an increased risk of developing colorectal cancer. Established risk factors for cancer among patients with inflammatory bowel disease (IBD) include the younger age at diagnosis, greater extent and duration of disease, increased severity of inflammation, family history of colorectal cancer and coexisting primary sclerosing cholangitis. Recent evidence suggests that current medical therapies and surgical techniques for inflammatory bowel disease may be reducing the incidence of this complication. Nonetheless heightened vigilance and a careful, comprehensive approach to prevent or minimize the complications of invasive cancer are warranted in this unique cohort of patients. Current guidelines for the prevention and early detection of cancer in this high risk population are grounded in the concept of an inflammation-dysplasia-carcinoma sequence. A thorough understanding of the definition and natural history of dysplasia in IBD, as well as the challenges associated with detection and interpretation of dysplasia are fundamental to developing an effective strategy for surveillance and prevention, and understanding the limitations of the current approach to prevention. This article reviews the current consensus guidelines for screening and surveillance of cancer in IBD, as well as presenting the evidence and rationale for chemoprevention of cancer and a discussion of emerging technologies for the detection of dysplasia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.